Treatment of Chronic Stable Asthma with Drugs Active on the 5-Lipoxygenase Pathway | Zendy

Jeffrey M. Drazen | Zendy; Elliot Israel | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Treatment of Chronic Stable Asthma with Drugs Active on the 5-Lipoxygenase Pathway

Author(s) -

Jeffrey M. Drazen,

Elliot Israel

Publication year - 1995

Publication title -

international archives of allergy and immunology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.696

H-Index - 100

eISSN - 1423-0097

pISSN - 1018-2438

DOI - 10.1159/000237013

Subject(s) - zileuton , asthma , arachidonate 5 lipoxygenase , leukotriene , medicine , lipoxygenase , airway , immunology , leukotriene receptor , pharmacology , anesthesia , enzyme , chemistry , arachidonic acid , biochemistry

It is now established that 5-lipoxygenase products are synthesized and released in the airway during asthmatic reactions. The importance of these products in the asthmatic response has been established through study of the effects of 5-lipoxygenase inhibitors and leukotriene D4 receptor antagonists in patients with chronic stable asthma. In this study we review the data demonstrating that chronic administration of zileuton, an inhibitor of 5-lipoxygenase, is associated with improved airway function, decreased asthma symptoms and decreased need for asthma medication use in patients with mild to moderate asthma.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research